Search Results - restifo

4 Results

Sort By:

Methods of Producing Thymic Emigrants from Induced Pluripotent Stem Cells

Abstract: Hematopoietic and pluripotent stem cells can be differentiated into T cells with potential clinical utility. Current approaches for in vitro T cell production rely on Notch signaling and artificial mimicry of thymic selection. However, these approaches result in unconventional or phenotypically aberrant T cells; which may lead to unpredictable...

Published: 4/8/2024 | Inventor(s): Raul Sakoda, Nicholas Klemen, Nicholas Restifo

Keywords(s): DIFFERENTIATION, Induced Pluripotent Stem Cells, IPSCS, RESEARCH MATERIAL, Restifo, T Cells, Thymic Environment, Tool

Category(s): TherapeuticArea > Infectious Disease, Application > Therapeutics, TherapeuticArea > Oncology, Collaboration Sought > Licensing

High-Throughput Generation of Induced Pluripotent Stem Cells Carrying Antigen-Specific T Cell Receptors from Tumor Infiltrated Lymphocytes

Abstract: One form of adoptive T cell therapy (ACT) consists of harvesting tumor infiltrating lymphocytes (TIL), screening and isolating TIL which display tumor antigen-specific T-cell receptors (TCR), expanding the isolated T cells in vitro, and reinfusing them into the patient for treatment. While highly active in the treatment of certain cancers...

Published: 4/8/2024 | Inventor(s): Raul Sakoda, S M Rafiqul Islam, Naritaka Tamaoki, Takuya Maeda, Nicholas Restifo

Keywords(s): act, adoptive cell therapy, ANTIGEN-SPECIFIC, Cancer Targets, Immunotherapy, Induced Pluripotent Stem Cells, iPSC, Restifo, Rosenberg, T Cell Receptors, TCR, TIL, Tumor Infiltrated Lymphocytes

Category(s): TherapeuticArea > Oncology, TherapeuticArea > Immunology, Application > Therapeutics, Collaboration Sought > Licensing

Potassium Hydroxy Citrate Promotes Longevity and Efficacy of Anti-Tumor T cells for Adoptive Cell Therapy (ACT)

Abstract: Adoptive cell therapy (ACT) using tumor-specific T cells can produce positive clinical responses in some cancer patients. Nevertheless, several obstacles to the successful use of ACT for the treatment of cancer and other conditions remain. For example, one or more of the in vivo persistence, survival, and antitumor activity of tumor-specific...

Published: 4/8/2024 | Inventor(s): Suman Vodnala, Nicholas Restifo, Rigel Kishton, Robert Eil

Keywords(s): act, adoptive cell therapy, Memory T Cells, Potassium Hydroxy Citrate, Restifo, Vodnala

Category(s): Application > Therapeutics, Collaboration Sought > Collaboration, TherapeuticArea > Oncology, Collaboration Sought > Licensing

Methods of Producing Effective T-cell Populations Using Akt Inhibitors

Abstract: Adoptive cell therapy (ACT) uses cancer reactive T-cells to effectively treat patients. However, several obstacles inhibit the successful use of ACT for cancer treatment. Current approaches for the expansion of T-cells may produce T-cells with a terminally differentiated phenotype that is associated with diminished anti-tumor activity and...

Published: 4/8/2024 | Inventor(s): Joseph Crompton, Nicholas Restifo

Keywords(s): act, AKT, CANCER, Immunotherapy. Adoptive Cell Therapy, Protein kinase B, Restifo, T-CELLS

Category(s): TherapeuticArea > Oncology, Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Application > Research Materials